Telehealth Medical Consent

Last Updated: 08/20/2026

By using telehealth services through PLEXUSDX, INC., you acknowledge and agree to the following:

Nature of Telehealth

Telehealth involves delivering healthcare services using electronic communication technologies.

This may include video consultations, messaging, or digital questionnaires.

Risks of Telehealth

Potential risks include:

  • Technical failures
  • Incomplete information due to electronic communication
  • Delays in evaluation or treatment

Benefits of Telehealth

Benefits may include:

  • Improved access to healthcare providers
  • Convenience and flexibility
  • Reduced travel time

Patient Responsibilities

You agree to:

  • Provide accurate medical information
  • Inform providers of any changes in your condition
  • Seek emergency care when appropriate

Consent to Treatment

By using the Platform, you consent to receiving telehealth services from licensed healthcare providers.

You may withdraw consent at any time by discontinuing use of the Platform.

Contact Information

PLEXUSDX, INC.
6110 McFarland Station Drive, #604
info@plexusdx.com
877-760-2333

Important information

Compounded medications are not approved by the FDA or reviewed for quality, safety, or efficacy.

Novo Nordisk, Inc. is the only United States company with FDA-approved products containing semaglutide, identified under the trade names Rybelsus®, Ozempic®, and Wegovy®.

Lilly USA LLC is the only United States company with FDA-approved products containing tirzepatide, identified under the trade names Zepbound® and Mounjaro®.

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.